Radiopharmaceutical developer Telix Pharmaceuticals Ltd (ASX:TLX) is expanding its push into AI-enabled cancer imaging through a new collaboration with Germany’s University Hospital Essen, ...

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), ...

Prostate tumors contain more microplastics than healthy prostate tissue, researchers from New York University Langone Health ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

New study finds microplastics in 90% of prostate cancer tumors, with double the concentration in cancerous tissue compared to ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial ResultsFourth quarter revenue growth of 19% to $29.5 million2025 revenue growth ...

A recent study by NYU Langone Health has found microplastics in 90% of prostate cancer tumors, revealing a potential link ...

Plastic has turned up in an unexpected place: inside most of the prostate tumors examined in a new study. NYU Langone Health ...